Geoff Buys a Gomer – Part II

When conducting due diligence on a company for investment (which I do regularly for private equity and VC firms) there are sort of three cardinal rules: Follow the money. Follow the assets. Follow the customers. Obviously in the case of 1) we are all trying to understand Anteo Diagnostic’s (ASX : ADO) investment thesis. Although I…

Orthosmell

Orthocell (ASX : OCC) has had two ASX “slaps” in the last month, to which the company pleaded “Schultz“. The first involved a bout of trading around the 6th of July. The second, a more detailed price query follow-up including some concerns in relation to activity on/around the 14th of July. Today we saw another…

The Incest of ASX Biopharma

It’s pretty hard to beat the Brits when it comes to situational comedy. As a dual-Australian/Canadian national educated in the UK, I suppose I have an intrinsic affinity for that dry, offhand style of humour. A few years ago, I stumbled across a brilliant comedy skit that visually captures precisely the fundamental reason why ASX biopharma is…

UBI : Not Universally Bad…

I have a love-hate relationship with diagnostics companies, especially point-of-care (PoC) diagnostics. Over the years I have probably looked a couple of hundred companies, always with interesting ideas and designs, often (sadly) with the usual unoriginal market opportunities (glucose, cardiac markers, troponin, hormones, etc.) and always where the core technology or innovation sits at the…

Much ADO About Nothing

Ok, that’s it. I’ve had it… The last couple of months I have endured a barrage of abusive emails from Anteo (ASX : ADO) shareholders and received a ton of crap on trading forums. I get that I am at best misguided and at worst, a flaming idiot. But I have decided that the only thing…

NRT, ANP, PYC, ACL, OBJ : A Week in Contrast

Last week was a pretty exciting week in Australian life sciences. Quite a bit happened, in fact I struggled to stay on top of it while being on vacation. We’ve seen a couple of good things happen, like PharmAxis, Sirtex recovery, etc. that are real bright spots on the Aussie biotech landscape. We’ve seen some…